Literature DB >> 7538844

Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3.

P J Fielder1, R G Rosenfeld, H C Graves, K Grandbois, C A Maack, S Sawamura, Y Ogawa, A Sommer, P Cohen.   

Abstract

Prostate specific antigen (PSA) has been shown to proteolyze IGFBP-3. However, the cleavage sites and mechanism of proteolysis are unknown. In this study, we proteolyzed recombinant human IGFBP-3 with PSA bound to a solid phase support. The reaction mixture was separated by centrifugation, with PSA remaining in the solid phase and the proteolyzed IGFBP-3 in the aqueous phase. The IGFBP-3 fragments were functionally analyzed by affinity labeling and Western ligand blotting (WLB). Further biochemical analyses were provided by silver staining of total protein and Western immunoblotting (WIB) of immunoreactive fragments with an IGFBP-3 specific antiserum (alpha-BP-3 g1). N-terminal sequence analysis was performed on filter-immobilized IGFBP-3 fragments, following size separation by SDS-polyacrylamide electrophoresis. PSA proteolyzed IGFBP-3 into at least 7 fragments (M(r) of 26 kDa to 13 kDa) as identified by silver staining and WIB. At least 3 fragments were visible by affinity labeling with radiolabeled IGF-I or IGF-II and 4 were weakly visible by WLB. These data indicate that some IGFBP-3 fragments retain their ability to bind IGF. N-terminal sequence analysis revealed at least 5 different proteolytic recognition sites for PSA in IGFBP-3. Three of the 5 sites were consistent with a 'kallikrein-like' enzymatic activity and 2 sites were consistent with a 'chymotryptic-like' enzymatic activity. The chymotryptic activity of PSA was further confirmed by the ability of alpha-1-antichymotrypsin and chymostatin to block PSA cleavage of radiolabeled IGFBP-3.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7538844

Source DB:  PubMed          Journal:  Growth Regul        ISSN: 0956-523X


  7 in total

1.  Twenty Years of PSA: From Prostate Antigen to Tumor Marker.

Authors:  Gabriela De Angelis; Harry G Rittenhouse; Stephen D Mikolajczyk; L Blair Shamel; Axel Semjonow
Journal:  Rev Urol       Date:  2007

2.  Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer.

Authors:  Scott D Cramer; Jielin Sun; S Lilly Zheng; Jianfeng Xu; Donna M Peehl
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

3.  Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.

Authors:  Fredrik Wiklund; S Lilly Zheng; Jielin Sun; Hans-Olov Adami; Hans Lilja; Fang-Chi Hsu; Pär Stattin; Jan Adolfsson; Scott D Cramer; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Henrik Grönberg; Jianfeng Xu
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

4.  NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation.

Authors:  Erin Muhlbradt; Ekaterina Asatiani; Elizabeth Ortner; Antai Wang; Edward P Gelmann
Journal:  Cancer Res       Date:  2009-03-03       Impact factor: 12.701

Review 5.  Molecular mechanisms and clinical management of cancer bone metastasis.

Authors:  Manni Wang; Fan Xia; Yuquan Wei; Xiawei Wei
Journal:  Bone Res       Date:  2020-07-29       Impact factor: 13.567

Review 6.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

Review 7.  Roles of the RANKL-RANK Axis in Immunity-Implications for Pathogenesis and Treatment of Bone Metastasis.

Authors:  Bo Li; Pengru Wang; Jian Jiao; Haifeng Wei; Wei Xu; Pingting Zhou
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.